Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Single-Site, Open-Label, Randomized, 2-Arm Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)

Next Previous
Trial Profile

Phase 2, Single-Site, Open-Label, Randomized, 2-Arm Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dantrolene (Primary)
  • Indications Heat stroke
  • Focus Registrational; Therapeutic Use
  • Sponsors Eagle Pharmaceuticals

    • Most Recent Events

    • 02 Mar 2020 According to an Eagle Pharmaceuticals media release, PDUFA date of July 8, 2020
    • 09 Jan 2020 According to an Eagle Pharmaceuticals media release, the Company has resubmitted its New Drug Application (NDA) for RYANODEX (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke (EHS), in addition to body cooling, to the U.S. Food and Drug Administration
    • 12 Nov 2019 According to an Eagle Pharmaceuticals media release, the company enrolled 10 additional patients in the trial (293560) at the 2019 Hajj pilgrimage held from 9th-14th Aug in Saudi Arabia, bringing the total number of patients recruited in 2015, 2018 and 2019 to 41.The company has submitted a plan to FDA that proposes reviewing the data collectively for all 41 patients. If FDA agrees with this plan,the company plans to resubmit the New Drug Application of RYANODEX for exertional heat stroke (EHS).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top